drugset / Trial / NCT05657418

A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer

NCT05657418

Phase 1 Terminated 8 enrolled Shanghai Junshi Bioscience Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS107 monotherapy and combination with Toripalimab in patients with Advanced pancreatic cancer.

Timeline

Start
2022-03-29
Primary completion
2025-01-04
Completion
2025-01-04

Drugs

EvaluationDrugModalityDoseRoute
Subject JS107 Unknown Intravenous
Background Toripalimab Monoclonal antibody